Last updated: February 16, 2026
What is NDC 57841-1300?
NDC 57841-1300 refers to Aspen's Ondansetron ODT (Orally Disintegrating Tablets), used primarily for preventing nausea and vomiting associated with chemotherapy, radiation therapy, or surgery.
Market Overview
Market Scope
- Primarily prescribed in oncology, post-operative, and radiation settings.
- Estimated worldwide market value in 2023: approximately $500 million.
- Top markets: United States, European Union, and Japan.
Market Drivers
- Rising cancer incidence globally, especially breast, lung, and colorectal cancers.
- Increased adoption of supportive care medications to manage chemotherapy side effects.
- Growing preference for orally administered formulations, including ODTs, due to ease of use.
Competitive Landscape
- Existing competitors include brand-name drugs like Zofran (GlaxoSmithKline) and generics from Teva, Mylan, and others.
- Aspen's entry with NDC 57841-1300 provides an alternative with potential cost advantages.
Price Trends and Projections
Current Pricing (as of Q1 2023)
- Average Wholesale Price (AWP): $0.70 per tablet.
- Federal Supply Schedule (FSS): Around $0.50 per tablet.
- Average selling prices (ASP) in pharmacies: Ranges from $0.60 to $0.80 per tablet, depending on the channel.
Price Factors
- Regulatory status: Approved as a generic, which constrains pricing.
- Manufacturing costs: Estimated at $0.15-$0.25 per unit.
- Reimbursement landscape: Medicaid, Medicare, and private insurers set reimbursement rates that influence net prices.
Future Price Projections (Next 3-5 Years)
| Year |
Projected AWP per Tablet |
Factors influencing prices |
| 2024 |
$0.65 |
Increased generic competition, potential price discounts for bulk purchasing |
| 2025 |
$0.60 |
Market saturation, continuing generic market pressure |
| 2026 |
$0.55 |
Further market penetration, cost-control measures |
| 2027 |
$0.50 |
Stable, low-price environment, market maturity |
Projections assume no significant patent challenges or supply disruptions.
Strategic Considerations
- Pricing positioning: Aspen can competitively price NDC 57841-1300 below established brands to gain market share.
- Market penetration: Given the high utilization rates, aggressive pricing could maximize volume rather than per-unit margins.
- Reimbursement and formularies: Securing inclusion in major formularies will drive volume and support sustainable pricing strategies.
Key Risks
- Market entry challenges due to incumbent dominance.
- Price erosion driven by new generic entrants or biosimilars.
- Regulatory changes affecting reimbursement policies.
Key Takeaways
- NDC 57841-1300 faces a competitive, established market dominated by branded drugs with significant generic presence.
- Current prices are approximately $0.60–$0.80 per tablet, with future trends pointing toward stabilization below $0.60.
- Market expansion opportunities exist in regions with rising cancer rates and supportive care medication demand.
- Price erosion is inevitable with increased generic competition; strategic focus on market volume and formulary access is essential.
FAQs
1. How does the price of Aspen's Ondansetron compare to the brand-name Zofran?
Zofran typically retails around $2.50 to $3.00 per tablet, significantly higher than Aspen’s generic-priced version.
2. What are the primary barriers to market entry for Aspen’s ondansetron?
Brand loyalty, existing distribution channels, and patent protections on branded versions are barriers; however, generic entry eases market penetration.
3. How are reimbursement policies expected to impact pricing?
Medicare and Medicaid set reimbursement rates that favor lower-cost generics, pressuring ASP to decline over time.
4. What regional markets are most promising for expansion?
Emerging markets in Latin America and Asia-Pacific exhibit increasing cancer treatment needs and growing acceptance of off-patent drugs.
5. Are biosimilars likely to influence the ondansetron market?
Biosimilars are less relevant for small-molecule drugs like ondansetron, but biosimilar competition could arise if new formulations or delivery mechanisms are developed.
Sources
- IQVIA. (2023). Global Oncology Supportive Care Market Report.
- FDA. (2022). Approval details for ondansetron generic formulations.
- ABCs of Drug Pricing. (2023). Trends in Generic Anti-emetics.
- GoodRx. (2023). Ondansetron pricing data.
- Pharma Intelligence. (2023). Competitive analysis of generic anti-emetics.
